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Epstein-Barr virus is pathogenically associated with a well defined group of lymphoid and epithelial tumors in
which the virus directly drives transformation of infected cells. Recent evidence however indicates that this virus
may infect a subpopulation of tumor cells in patients with chronic lymphocytic leukemia (CLL) and EBV infection
has been also associated with Richter transformation in a fraction of cases. We herein review available data sug-
gesting a possible role of EBV as a direct or micro-environmental progression factor in a subset of CLL.
Introduction
The Epstein-Barr virus (EBV) was first identified 40
years ago in cultured Burkitt’s lymphoma cells when no
human lymphoid cell had ever been maintained in cul-
ture [1]. EBV has a world-wide distribution being able
to establish a lifelong infection in more than 90% of
individuals. Primary infection is usually asymptomatic
and only when it is delayed until adolescence or adult-
hood a benign lymphoproliferative disease, known as
infectious mononucleosis (IM), may occur. The main
site of EBV persistence in vivo is represented by latently
infected B cells showing features of resting memory B
lymphocytes [2,3]. Under normal circumstances, EBV is
able to establish a persistent infection in vivo without
affecting the behavior of B lymphocytes. To do so, the
virus has evolved an elegant strategy based on the subtle
exploitation of virtually all aspects of B cell physiology.
The final outcome of the interaction between EBV and
the infected host is the establishment of a nonpatho-
genic latent infection of memory B lymphocytes that
allows the virus to persist for the lifetime. Evidence
accumulated so far, in particular the presence of EBV
genomes and the constant expression of viral proteins,
strongly support the involvement of EBV in the patho-
genesis of a wide spectrum of human malignancies.
These include lymphomas of B, T and NK cell origin
such as the immunoblastic lymphoma of immunosup-
pressed, endemic Burkitt’s lymphoma (BL), Hodgkin’s
Lymphoma (HL), and some T/NK cell lymphoma, but
also carcinomas of the nasopharynx and stomach and
leiomyosarcomas arising in organ transplant patients
and HIV-infected individuals [4]. EBV-induced immorta-
lization/transformation is mediated by the activity of
viral proteins that interfere with crucial cellular path-
ways controlling growth and/or survival. These viral
proteins act cooperatively and may induce different bio-
logic effects in different cellular backgrounds [4]. On
the basis of the different pattern of latent EBV genes
expressed in EBV-associated tumors, three main types
of virus latency have been identified. Latency I is the
more restricted form of viral gene expression and char-
acterizes BL, which expresses only the EBV nuclear anti-
gen (EBNA)-1 and the EBV RNAs (EBERs). In contrast,
latency III involves the unrestricted expression of all the
6 EBNAs together with the latent membrane proteins
(LMP)-1 and LMP-2. This type of latency mainly occurs
in the setting of severe immune suppression and charac-
terizes post-transplant and HIV-associated lymphoproli-
ferative disorders, and is usually observed in EBV-
immortalized lymphoblastoid cell lines in vitro. Latency
II is an intermediate form of virus latency in which,
besides EBNA-1 and EBERs, only LMP-1 and -2 are
expressed. This pattern of EBV gene expression is
observed in HL, T/NK cell lymphoma, and nasopharyn-
geal carcinoma (NPC).
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viruses that behave as direct transforming agents. In
fact, in classical EBV-associated tumors, the virus gen-
ome is present in virtually all neoplastic cells, which
show the expression of viral RNAs and proteins that
variously contribute to the induction of the transformed
phenotype. On the basis of these features and of the
strict association with distinct tumor types, EBV has
been classified as a group I carcinogen. An additional
compelling factor is the presence of homogeneous (clo-
nal) EBV episomes detected with the use of the virus
termini assay in several EBV-related tumors (HL, NPC,
BL) as well as in some pre-neoplastic lesions. These
findings suggest that these tumors develop from a single
cell that was infected by EBV before the outgrowth and
are consistent with a role for EBV in the early phases of
tumor development.
Besides the well defined group of tumors pathogeni-
cally associated with EBV according to the criteria men-
tioned above, the presence of this herpesvirus has been
variably detected in a broad spectrum of other tumors
for which a causal role of EBV seems unlikely. These
tumors include also chronic lymphocytic leukemia. We
herein briefly review available data suggesting a possible
role of EBV as a direct or microenvironmental progres-
sion factor in a fraction of CLL.
Chronic lymphocytic leukemia and Richter’s
syndrome
Chronic lymphocytic leukemia (CLL) is the most com-
mon type of adult leukemia in the United States and
Western Europe. CLL cells are small lymphoid B cells
with scant cytoplasm having a regular outline. Nuclei
contain clumped chromatin and nucleoli are usually
absent. On bone marrow and peripheral blood smears
the CLL variant with increased prolymphocytes (CLL/
PLL), consists of more than 10%, but less than 55% pro-
lymphocytes. Bone marrow histologic pattern may be
nodular, interstitial, diffuse, or a combination of the
three. These patterns correlate with prognosis [5]. CLL
cells express surface IgM or IgM and IgD, CD5, CD19,
and CD23. Ig genes are rearranged. 40-50% of cases are
un-mutated and 50-60% show somatic hypermutations.
There is a group of genes that distinguishes the two
genetic subytpes. ZAP-70 is among the genes whose
expression is associated with an IgHV un-mutated CLL
genotype [5]. About 50% of CLL show 13q deletion,
about 20% trisomy 12 and, less commonly, other geno-
mic abnormalities. Low stage patients with mutated CLL
have a better prognosis than those with un-mutated
CLL. ZAP-70 and CD38 expression of are associated
with a poor prognosis [5].
A small fraction (approximately 2-8%) of patients with
CLL develop diffuse large B-cell lymphoma (DLBCL).
This event has been termed Richter’s syndrome or Rich-
ter’s transformation [6] and is associated with poor
response to treatment and low survival times [5]. Rich-
ter’s syndrome is histologically characterized by conflu-
ent sheets of large cells that may resemble centroblast-
or immunoblast-like cells. The majority of the reported
DLBCL occurring in patients with CLL are clonally
related to the previous CLL [7,8]. An interesting finding
is the occurrence of scattered Hodgkin and Reed Stern-
berg (HRS)-like cells in the background. In contrast to
true Hodgkin lymphoma arising in CLL patients, the
reactive typical background is absent and the HRS-like
cells are surrounded by neoplastic B-cells. These HRS-
like cells show evidence of EBV infection (Figure 1).
EBV and chronic lymphocytic leukemia
EBV infection is only infrequently detected in CLL by
conventional diagnostic approaches. This is consistent
with in vitro findings indicating that CLL cells do not
regularly become activated or immortalized after expo-
sure to EBV [9], although this can be achieved following
cytokine activation [10]. It has been shown, in particular,
that the combined treatment with Staphylococcus aureus
Cowan I (SAC), MP6-thioredoxin, and interleukin 2 can
render CLL cells susceptible to EBV infection in vitro
[10]. Therefore, although basally refractory, CLL cells
may become occasionally infected by EBV in vivo pro-
vided that mitogenic and activating signals are available
within the microenvironment. In CLL cells, however,
the expression of the EBV-encoded nuclear proteins
EBNAs is not followed by entrance into the cell cycle.
In fact, unlike what observed in normal B lymphocytes,
EBV-infected CLL cells remain resting and do not
express c-myc, cyclin D2, or pRb, whereas the p27 cell
cycle inhibitor is not down-regulated [11].
In CLL cases showing EBV infection, EBV markers are
however detectable only in a subpopulation of tumor
cells [12,13]. Notably, several studies have reported that
expression of EBERs detected by in situ hybridization
correlated with progressive or accelerated clinical
courses [13-16]. EBERs are small non-coding RNAs
abundantly expressed in latently infected cells that play
critical role in B cell transformation and induction of
resistance to apoptosis [17], and may therefore directly
contribute to CLL progression. Further characterization
of EBV infection in this setting allowed the demonstra-
tion of LMP-1 mRNA expression in isolated CLL cells
but not in normal resting B lymphocytes [18]. More
recently, LMP-1 transcriptional activity was detected in
a significant proportion of CLL cases (14% vs.1 %o f
healthy controls) [19]. Notably, CLL patients showing
LMP-1 mRNA expression had a higher extent of mar-
row involvement [19]. Although a confirmation that
LMP-1 is expressed also at the protein level is still
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role for EBV in the malignant progression of the disease.
EBV infection has been also associated with a fraction of
CLL transformation to diffuse large cell lymphoma or
Richter syndrome, particularly in cases displaying a high
number of Reed-Sternberg-like cells [15,20-23]. Cases of
CLL transformation to HL have been also reported
[23,24]. Considering that LMP-1 drives the morphologic
and transcriptional changes characteristic of Hodgkin/
Reed-Sternberg cells [25], the detection of LMP-1
expression in tumor cells of a fraction of CLL cases is
particularly intriguing and deserves further investigation.
In some, but not all cases, the malignant transformation
involves cells originating from the CLL clone, as shown
by immunoglobulin gene rearrangement studies [26-29],
further supporting the role of secondary EBV infection
as a possible cyto-morphologic and clinical progression
factor for CLL. In clonally distinct cases, the immune
suppression induced by drugs such as fludarabine or
anti-CD52 antibodies may favor the outgrowth of an
unrelated, EBV-infected B cell clone that may lead to a
clinically aggressive disease resembling EBV-associated
lymphoproliferations of immunosuppressed patients.
These cases should be distinguished from Richter syn-
drome, probably representing a novel type of immuno-
deficiency-related lymphoma.
Besides behaving as a direct drive of neoplastic pro-
gression in EBV-infected CLL cells, the presence of EBV
within tumor microenvironment could also indirectly
contribute to the malignant evolution of the disease.
Indeed, EBV may infect a subpopulation of CLL cells
and/or may be carried by bystander normal B lympho-
cytes. EBV infection and, particularly, LMP-1 expression,
by CLL cells may promote angiogenesis by inducing
IL-8 [30], and increasing the production of vascular
endothelial growth factor [31]. Moreover, EBV may
induce/enhance the production of cytokines, such as cel-
lular IL-10 (cIL-10), able to promote B cell proliferation
and inhibit T cell responses [32]. Notably, serum cIL-10
levels are increased in CLL patients and correlate with
adverse disease features and short survival [33]. Intrigu-
ingly, assays measuring both EBV-derived (viral IL-10)
and human cIL-10 yielded higher values than assays spe-
cifically quantifying human cIL-10 [33]. These findings
indirectly indicate that, in a fraction of CLL cases, EBV
infection is not silent, being associated with enhanced
production of viral IL-10. EBV may also contribute to a
local immune suppression through the production of
hydrophobic peptides derived from the first transmem-
brane domain of LMP-1 [34]. These peptides, in fact,
potently inhibit both cytotoxic T lymphocyte and nat-
ural killer cell responses in vitro [34].
Concluding remarks and future perspectives
In CLL, evidence for EBV infection was obtained only in
a subset of cases and, notably, only in a variable fraction
Figure 1 Richter’s transformation of a CLL case. In situ EBER hybridization shows nuclear staining in giant Hodgkin/Reed-Sternberg-like
cells (660×).
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stant presence of EBV genome in all tumor cells of malig-
nancies pathogenically linked to the virus and argue
against a causal role for EBV in the early phases of CLL
development. Although a partial loss of viral genomes
can not be formally excluded in these cases, this possibi-
lity appears however unlikely. Moreover, the fact that
viral products necessary to sustain the transformed phe-
notype may be expressed only by a fraction of tumor
cells further weakens the hypothesis of a pathogenic
involvement of EBV in this tumor. Although further stu-
dies are required to elucidate this complex and still
debated issue, available evidence briefly reviewed herein
is consistent with a possible role of EBV infection as a
secondary event occurring after cell transformation and
affecting a subpopulation of CLL cells in which the virus
may promote the evolution to a more malignant pheno-
type. The possible prognostic role of EBV-driven produc-
tion of factors able to promote CLL cell growth,
angiogenesis and to inhibit tumor-specific immune
responses deserves to be carefully investigated by pro-
spective studies. If such progression mechanisms will be
conclusively demonstrated, the use of antagonists or inhi-
bitors of molecules produced by EBV-infected cells could
represent a potentially attractive therapeutic approach.
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